Rock Springs Capital Management LP trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 6.4% in the 1st quarter, Holdings Channel reports. The firm owned 98,700 shares of the company’s stock after selling 6,700 shares during the quarter. Eli Lilly and Company accounts for 5.4% of Rock Springs Capital Management LP’s holdings, making the stock its 2nd biggest holding. Rock Springs Capital Management LP’s holdings in Eli Lilly and Company were worth $90,781,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Empowered Funds LLC grew its holdings in shares of Eli Lilly and Company by 112.9% in the first quarter. Empowered Funds LLC now owns 137,886 shares of the company’s stock worth $126,823,000 after purchasing an additional 73,133 shares during the last quarter. Evelyn Partners Asset Management Ltd lifted its holdings in Eli Lilly and Company by 15.4% during the 1st quarter. Evelyn Partners Asset Management Ltd now owns 1,441 shares of the company’s stock valued at $1,325,000 after buying an additional 192 shares in the last quarter. Evelyn Partners Investment Management LLP lifted its holdings in Eli Lilly and Company by 39.3% during the 1st quarter. Evelyn Partners Investment Management LLP now owns 7,228 shares of the company’s stock valued at $6,648,000 after buying an additional 2,040 shares in the last quarter. Evelyn Partners Investment Management Services Ltd boosted its position in Eli Lilly and Company by 19.3% in the 1st quarter. Evelyn Partners Investment Management Services Ltd now owns 8,949 shares of the company’s stock valued at $8,231,000 after buying an additional 1,450 shares during the period. Finally, Eversept Partners LP boosted its position in Eli Lilly and Company by 78.9% in the 1st quarter. Eversept Partners LP now owns 19,000 shares of the company’s stock valued at $17,476,000 after buying an additional 8,377 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Price Performance
NYSE:LLY opened at $1,197.88 on Tuesday. The firm has a market cap of $1.13 trillion, a price-to-earnings ratio of 42.55, a PEG ratio of 1.48 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The firm’s fifty day moving average is $1,140.74 and its two-hundred day moving average is $1,041.08. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.
Eli Lilly and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 24.58%.
Wall Street Analyst Weigh In
LLY has been the topic of a number of research reports. UBS Group raised their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. Sanford C. Bernstein raised their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,283.64.
View Our Latest Stock Analysis on Eli Lilly and Company
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
